Krystal Biotech, Inc. Forecast, price target & analysts
Krystal Biotech, Inc. Target price 2025 - Analyst rating & recommendation
Krystal Biotech, Inc. Classifications & Recommendation:
Krystal Biotech, Inc. Price Target
| Target Price | $206.04 |
| Price | $164.97 |
| Potential |
24.90%
register free of charge
|
| Number of Estimates | 13 |
|
13 Analysts have issued a price target Krystal Biotech, Inc. 2026 .
The average Krystal Biotech, Inc. target price is $206.04.
This is
24.90%
register free of charge
$264.60
60.39%
register free of charge
$167.66
1.63%
register free of charge
|
|
| A rating was issued by 18 analysts: 16 Analysts recommend Krystal Biotech, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Krystal Biotech, Inc. stock has an average upside potential 2026 of
24.90%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 290.52 | 390.25 |
| 473.02% | 34.33% | |
| EBITDA Margin | 37.83% | 39.36% |
| 120.80% | 4.04% | |
| Net Margin | 30.69% | 37.53% |
| 42.36% | 22.29% |
13 Analysts have issued a sales forecast Krystal Biotech, Inc. 2025 . The average Krystal Biotech, Inc. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Krystal Biotech, Inc. EBITDA forecast 2025. The average Krystal Biotech, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
14 Krystal Biotech, Inc. Analysts have issued a net profit forecast 2025. The average Krystal Biotech, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 3.00 | 5.06 |
| 669.23% | 68.67% | |
| P/E | 32.59 | |
| EV/Sales | 10.49 |
14 Analysts have issued a Krystal Biotech, Inc. forecast for earnings per share. The average Krystal Biotech, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Krystal Biotech, Inc....
Current Krystal Biotech, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 15 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Aug 22 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 22 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Aug 05 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Aug 05 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jul 25 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Jul 25 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 15 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Aug 22 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 22 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Aug 05 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Aug 05 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jul 25 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Jul 25 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
